<DOC>
	<DOCNO>NCT00793247</DOCNO>
	<brief_summary>This study design investigate clinical safety , tolerability efficacy prucalopride improve symptom associate chronic intestinal pseudo-obstruction ( CIP ) subject CIP . The study hypothesis prucalopride dose 4 mg safe , well tolerate , efficacious improves symptom associate CIP .</brief_summary>
	<brief_title>Efficacy Study Prucalopride Treat Chronic Intestinal Pseudo-Obstruction ( CIP )</brief_title>
	<detailed_description>This phase II , double-blind , placebo-controlled , two-treatment four period cross-over trial investigated clinical safety , tolerability efficacy R093877 ( prucalopride ) improve symptom associate chronic intestinal pseudo-obstruction ( CIP ) subject CIP . Subjects treat 4 period 12 week either R093877 2 mg ( 2 period ) placebo ( 2 period ) . In first second 6 month period , placebo ( PLA ) active drug ( PRU ) treatment period . There wash-out period . In total,7 subject randomize ; 2 assign PLA-PRU-PLA-PRU , 2 PRUPLA-PRU-PLA , 2 PLA-PRU-PRU-PLA , 1 PRU-PLA-PLA-PRU sequence group . Subjects allow use 4 mg prucalopride per day 2 mg dose seem insufficient . Two subject use average 3 mg prucalopride per day active drug period .</detailed_description>
	<mesh_term>Intestinal Pseudo-Obstruction</mesh_term>
	<criteria>Aged â‰¥ 18 year ; A history chronic pseudoobstruction least 3 month ; Subjects chronic idiopathic pseudoobstruction chronic pseudoobstruction secondary scleroderma intestinal polyneuropathy ; CIP diagnose Bariumimaging study show presence dilatation part small bowel ( without presence large bowel dilatation ) ; Subjects organic obstruct lesion cause intestinal obstruction ; Current uncontrolled cardiovascular lung disease , neurologic psychiatric disorder ( include substance abuse exception nicotin ) , alcoholism , cancer AIDS endocrine disorder ; Impaired renal function A serum amylase , serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) concentration &gt; 2 time normal limit ; Laboratory value outside reference range laboratory , unless explain disease felt investigator clinically unimportant ; Use disallow concomitant therapy ; Female subject pregnant wish become pregnant course trial lactating ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>